SEC Form 4 · accession 0000899866-17-000157
ALEXION PHARMACEUTICALS, INC. · ALXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Julie O'Neill
Officer — EVP. Global Operations
Period of report
Aug 28, 2017
Accepted (ET)
Aug 30, 2017 · 6:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000899866
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $.0001 per shareF1 | Aug 28, 2017 | S | 11,160 | $140.00 | D | 26,704 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.